Recursion Pharmaceuticals
Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City-based AI-enabled drug discovery company that operates the Recursion Operating System (Recursion OS), a vertically integrated platform combining automated wet-lab cellular phenomics, transcriptomics (Trekseq), proteomics, ADME, chemistry, and patient data with machine learning to map biology and design drug candidates. The platform runs on BioHive-2, a NVIDIA-built supercomputer ranked among the top global systems and dedicated to biopharma workloads, and is fed by 50+ petabytes of proprietary biological and chemical data. In November 2024 Recursion completed the acquisition of Exscientia, folding Exscientia's generative AI chemistry, Centaur Chemist, and clinical pipeline into the combined company; Recursion now runs more than 10 clinical and preclinical programs (REC-4881 for FAP, REC-3565 MALT1 inhibitor, REC-1245 RBM39 for biomarker-enriched solid tumors and lymphomas, REC-617 CDK7 inhibitor, REC-994 for cerebral cavernous malformation, REC-2282 for NF2- mutated meningiomas, REC-4209 for IPF, REC-7735 for HSD obesity), 10+ advanced discovery programs, and 10+ partnered programs across Roche (Genentech), Bayer, Sanofi, and Merck KGaA (Darmstadt). Recursion does not currently expose paid commercial APIs to external developers; assets and data access are delivered through licensing, scientific collaborations, and the MapApp web product. Externally, Recursion ships substantial open tooling: the RxRx family of open phenomics datasets (RxRx1, RxRx2, RxRx3, RxRx3-core, RxRx19a, RxRx19b) hosted at rxrx.ai and Hugging Face, the OpenPhenom-S/16 foundation model (released on Hugging Face and Google Cloud's Model Garden, with Phenom-Beta on NVIDIA BioNeMo), the MolE molecular foundation model, the gflownet library for graph and molecular generative modeling, SynFlowNet/synflownet-boltz for retrosynthesis-aware molecular design, maes_microscopy (NeurIPS 2023 spotlight masked autoencoders for cell microscopy), and rxrx1-utils for the NeurIPS 2019 CellSignal competition. The combination positions Recursion as a Tier-2 AI drug discovery provider with no commercial API surface but a meaningful open-source and open-model presence aimed at the computational biology research community.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Recursion Pharmaceuticals the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Recursion Pharmaceuticals scores 7.9/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Recursion Pharmaceuticals
Each block below is one kind of artifact we hold for Recursion Pharmaceuticals. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Recursion Pharmaceuticals — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Get Started 1
Portal, sign-up, and the first successful call
Build 7
SDKs, sample code, and the tooling you integrate with
Scroll within the panel for all 7 ·
Access & Security 1
Authentication, authorization, and security posture
Learn 1
Tutorials, courses, talks, and written guidance
Company 8
The organization behind the API
Scroll within the panel for all 8 ·
Other 14
Properties that don't map to a standard resource type
Scroll within the panel for all 14 ·
← All providers · Data indexed from github.com/api-evangelist/recursion-pharmaceuticals · machine-readable index on apis.io